VANCOUVER, British Columbia and WARMINSTER, Pa., June 02, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS ), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company will be participating in the following investor conferences:
- Jefferies 2017 Global Healthcare Conference, June 6-9, 2017, New York, and
- JMP Securities Life Sciences Conference, June 20-21, 2017, New York.
About Arbutus Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com .
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604-419-3200 Email: acutler@arbutusbio.com Tiffany Tolmie Manager, Investor Relations Phone: 604-419-3200 Email: ttolmie@arbutusbio.com Media David Schull Russo Partners Phone: 858.717.2310 Email: david.schull@russopartnersllc.com